Biocon buys Viatris biosimilars for $3.3bn, eyes IPO
pharmaphorum
FEBRUARY 28, 2022
India’s Biocon has expanded its pipeline of biosimilars with a $3.3 Biocon’s partnership with Mylan – which merged with Pfizer’s Upjohn to form Viatris in 2020 – dates back more than a decade and has generated a number of biosimilars including insulin analogues, antibodies and recombinant proteins.
94 
Let's personalize your content